238120 — Aligned Genetics Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩64bn
- KR₩54bn
- KR₩15bn
- 35
- 32
- 76
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 117 | 468 | 5,542 | 2,333 | 3,236 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | -99.1 | -231 | -1,300 | 966 | 841 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -74.7 | -877 | -2,873 | -1,876 | -1,909 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 659 | 35.7 | 136 | 2,222 | 2,849 |
Capital Expenditures | -283 | -106 | -202 | -1,869 | -880 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1,818 | 1,271 | -3,466 | 4,406 | 2,171 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 1,534 | 1,166 | -3,668 | 2,537 | 1,290 |
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -204 | -228 | 3,633 | -176 | -193 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2,032 | 741 | 498 | 4,559 | 4,231 |